Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 3, 2010, Pages 1149-1162

  Seo, Hee Jeong ^a   Kim, Min Ju ^a   Lee, Suk Ho ^a   Lee, Sung Han ^a   Jung, Myung Eun ^a   Kim, Mi Soon ^a   Ahn, Kwangwoo ^a   Kim, Jeongmin ^a   Lee, Jinhwa ^a  

^a Green Cross Company   (South Korea)

Author keywords

Carboxamide; CB1 receptor; Pyrazole; Rimonabant; Triazole

Indexed keywords

4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 1 (2 CHLOROPHENYL) 5 (4 CHLOROPHENYL) N (CYCLOHEXYLMETHYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 1 (2 CHLOROPHENYL) 5 (4 CHLOROPHENYL) N CYCLOHEPTYL 1H PYRAZOLE 3 CARBOXAMIDE; 4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 1 (2 CHLOROPHENYL) 5 (4 CHLOROPHENYL) N CYCLOHEXYL 1H PYRAZOLE 3 CARBOXAMIDE; 4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 5 (4 BROMOPHENYL) 1 (2 CHLOROPHENYL) N CYCLOHEPTYL 1H PYRAZOLE 3 CARBOXAMIDE; 4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 5 (4 BROMOPHENYL) 1 (2 CHLOROPHENYL) N CYCLOHEXYL 1H PYRAZOLE 3 CARBOXAMIDE; 4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 5 (4 BROMOPHENYL) 1 (2,4 DICHLOROPHENYL) N (PIPERIDIN 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 5 (4 BROMOPHENYL) N (CYCLOHEXYLMETHYL) 1 (2,4 DICHLOROPHENYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 5 (4 BROMOPHENYL) N [1 (4 BROMOPHENYL)ETHYL] 1 (2 CHLOROPHENYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 5 (4 BROMOPHENYL) N [1 (4 BROMOPHENYL)ETHYL] 1 (2,4 DICHLOROPHENYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 5 (4 BROMOPHENYL) N CYCLOHEPTYL 1 (2,4 DICHLOROPHENYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 5 (4 BROMOPHENYL) N CYCLOHEXYL 1 (2,4 DICHLOROPHENYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) N (2 METHYLCYCLOHEXYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) N (4 METHYLCYCLOHEXYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) N (PIPERIDIN 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 5 (4 CHLOROPHENYL) N (CYCLOHEXYLMETHYL) 1 (2,4 DICHLOROPHENYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 5 (4 CHLOROPHENYL) N CYCLOHEPTYL 1 (2,4 DICHLOROPHENYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 5 (4 CHLOROPHENYL) N CYCLOHEXYL 1 (2,4 DICHLOROPHENYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 [(1H 1,2,4 TRIAZOL 1 YL)METHYL] 5 (4 CHLOROPHENYL) N CYCLOPENTYL 1 (2,4 DICHLOROPHENYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 [(1H1,2,4 TRIAZOL 1 YL)METHYL] 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) N (2,6 DIMETHYLPIPERIDIN 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; [4 ((1H 1,2,4 TRIAZOL 1 YL)METHYL) 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 1H PYRAZOL 3 YL)(4 (2,3 DIMETHYLPHENYL)PIPERAZIN 1 YL]METHANONE; ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; DRINABANT; IBIPINABANT; OTENABANT; RIMONABANT; SP 945598; TARANABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN; OBESITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; MALE; MICE; MICE, INBRED C57BL; PROTEIN BINDING; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 75149112285     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.12.040     Document Type: Article

References (35)

1. Bays H.E. Obes. Res. 12 (2004) 1197
2. Kurukulasuriya L.R., and Sowers J.R. Therapy 4 (2007) 497
3. Tremblay A., and Doucet E. Obes. Rev. 1 (2000) 27
4. Patel P.N., and Pathak R. Am. J. Health-Syst. Pharm. 64 (2007) 481
5. Bray G.A. J. Med. Chem. 49 (2006) 4001
6. Lee J., Song K.-S., Kang J., Lee S.H., and Lee J. Curr. Top. Med. Chem. 9 (2009) 564
7. Padwal R.S., and Majumdar S.R. Lancet 369 (2007) 71
8. Szmitko P.E., and Verma S. Atherosclerosis 199 (2008) 248
9. Barth F. Ann. Rep. Med. Chem. 40 (2005) 103
10. Kirkham T.C. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284 (2003) R343
11. Cervino C., Pasquali R., and Pagotto U. Mini-Rev. Med. Chem. 7 (2007) 21
12. Barth, F.; Cassellas, P.; Congy, C.; Martinez, S.; Rinaldi, M. US patent 54,62,960, 1995.
13. Lin L.S., Lanza T.J., Jewell J.P., Liu P., Shah S.K., Qi H., Tong X., Wang J., Xu S., Fong T.M., Shen C.-P., Lao J., Chen J., Shearman L.P., Stribling D.S., Rosko K., Strack A., Marsh D.J., Feng Y., Kumar S., Samuel K., Yin W., Van der Ploeg L., Goulet M.T., and Hagman W.K. J. Med. Chem. 49 (2006) 7584
14. Chen C.-y., Frey L.F., Shultz S., Wallace D.J., Marcantonio K., Payack J.F., Vazquez E., Springfield S.A., Zhou G., Liu P., Kieczykowski G.R., Chen A.M., Phenix B.D., Singh U., Strine J., Izzo B., and Krska S.W. Org. Process Res. Dev. 11 (2007) 616
15. Lin L.S., Ha S., Ball R.G., Tsou N.N., Castonguay L.A., Doss G.A., Fong T.M., Shen C.P., Xiao J.C., Goulet M.T., and Hagmann W.K. J. Med. Chem. 51 (2008) 2108
16. Griffith D.A., Hadcock J.R., Black S.C., Iredale P.A., Carpino P.A., DaSilva-Jardine P., Day R., DiBrino J., Dow R.L., Landis M.S., O'Connor R.E., and Scott D.O. J. Med. Chem. 52 (2009) 234
17. Lange J.H.M., and Kruse C.G. Drug Discovery Today 10 (2005) 693
18. Shim J.Y., Welsh W.J., Cartier E., Edwards J.L., and Howlett A.C. J. Med. Chem. 45 (2002) 1447-1459
19. Barth, F.; Congy, C.; Gueule, P.; Rinaldi-Carmona, M.; Van Brodeck, D. PCT Patent WO 2006/087480 A1, 2006
20. Moritani, Y. PCT Patent WO 2007/046550 A1, 2007.
21. Lee S.H., Seo H.J., Lee S.-H., Jung M.E., Park J.-H., Park H.-J., Yoo J., Yun H., Na J., Kang S.Y., Song K.-S., Kim M.-a., Chang C.-H., Kim J., and Lee J. J. Med. Chem. 51 (2008) 7216
22. Lee S.H., Seo H.J., Kim M.J., Kang S.Y., Song K.-S., Lee S.-H., Jung M.E., Kim J., and Lee J. Bioorg. Med. Chem. Lett. 19 (2009) 1899
23. Seo H.J., Kim M.J., Song K.-S., Lee S.-H., Jung M.E., Kim M.-S., Park H.-J., Yoo J., Chang C.-H., Kim J., and Lee J. Future Med. Chem. 1 (2009) 947
24. Lee S.H., Seo H.J., Kim M.J., Kang S.Y., Lee S.-H., Ahn K., Lee M., Han H.-K., Kim J., and Lee J. Bioorg. Med. Chem. Lett. 19 (2009) 6632
25. (a) Barth, F.; Congy, C.; Martinez, S.; Rinaldi, M. US Patent 6028,084, 2000
26. Amengual, R.; Marsol, C.; Mayeux, E.; Sierra, M.; Wagner, P. PCT Patent WO 2006/133926 A1, 2006.
27. Nielsen F.E., Ebdrup S., Jensen A.F., Ynddal L., Bodvarsdottir T.B., Stidsen C., Worsaae A., Boonen H.C.M., Arkhammar P.O.G., Fremming T., Wahl P., Kornø H.T., and Hansen J.B. J. Med. Chem. 49 (2006) 4127
28. Kuster J.E., Stevenson J.I., Ward S.J., D'Ambra T.E., and Haycock D.A. J. Pharmacol. Exp. Ther. 264 (1993) 1352
29. Murphy J.W., and Kendall D.A. Biochem. Pharmacol. 65 (2003) 1623
30. Dow R.L., Hadcock J.R., Scott D.O., Schneider S.R., Paight E.S., Iredale P.A., Carpino P.A., Griffith D.A., Hammond M., and DaSilva-Jardine P. Bioorg. Med. Chem. Lett. 19 (2009) 5351
31. Kang S.Y., Lee S.-H., Seo H.J., Jung M.E., Ahn K., Kim J., and Lee J. Bioorg. Med. Chem. Lett. 18 (2008) 2384
32. Hildebrandt A.L., Kelly-Sullivan D.M., and Black S.C. Eur. J. Pharmacol. 462 (2003) 125
33. 50 = 5.0 ± 1.0 nM) in each different assay (>1800 compounds tested). Therefore, we believe that all SAR discussions in the manuscript in the manuscript are scientifically meaningful.
34. Bouaboula M., Perrachon S., Milligan L., Canat X., Rinaldi-Carmona M., Potier M., Barth F., Calandra B., Pecceu F., Lupker J., Maffrand J.P., Le Fur G., and Casellas P. J. Biol. Chem. 272 (1997) 22330
35. Calandra B., Portier M., Kerneis A., Delpech M., Carillon C., Le Fur G., Ferrara P., and Shire D. Eur. J. Pharmacol. 374 (1999) 445